Neuroleptic Malignant Syndrome in an Adolescent Receiving Olanzapine‐Lithium Combination Therapy

A 16‐year‐old boy developed fever, generalized rigidity, leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and lithium. When both drugs were discontinued, his fever and rigidity subsided and biochemical irregularities spontaneously returned to normal, without any complications. Classic neuroleptic malignant syndrome (NMS) was diagnosed. Concomitant administration of lithium with olanzapine may place patients at risk for NMS. Clinicians need to be aware of this rare but potentially fatal side effect in patients of all ages, and especially in adolescents receiving both drugs.

[1]  R. Reeves,et al.  Atypical Neuroleptic Malignant Syndrome Associated with Olanzapine , 2002, Pharmacotherapy.

[2]  R. Procyshyn,et al.  Olanzapine associated weight gain, Hyperglycemia and Neuroleptic Malignant Syndrome: case report , 2002, International Journal of Geriatric Psychiatry.

[3]  A. Aboraya,et al.  Neuroleptic malignant syndrome associated with risperidone and olanzapine in first-episode schizophrenia. , 2002, The West Virginia medical journal.

[4]  J. Vázquez-Barquero,et al.  Neuropletic malignant syndrome and olanzapine. , 2000, Journal of clinical psychopharmacology.

[5]  S. Stanfield,et al.  Neuroleptic malignant syndrome associated with olanzapine therapy: a case report. , 2000, The Journal of emergency medicine.

[6]  E. Leinonen,et al.  Neuroleptic malignant syndrome during olanzapine and levomepromazine treatment , 2000, Acta psychiatrica Scandinavica.

[7]  K. Ilett,et al.  Relapsing Vivax Malaria, Chloroquine Toxicity, Anxiety, or Alcohol Misuse? , 2000, The Annals of pharmacotherapy.

[8]  C. Alderman,et al.  Possible Neuroleptic Malignant Syndrome Associated with Olanzapine , 2000, The Annals of pharmacotherapy.

[9]  H. Knobler,et al.  Recurrence of neuroleptic malignant syndrome with olanzapine treatment. , 1999, The American journal of psychiatry.

[10]  A. Alao,et al.  Cybersuicide: the Internet and suicide. , 1999, The American journal of psychiatry.

[11]  J. Levenson.  Neuroleptic malignant syndrome after the initiation of olanzapine. , 1999, Journal of clinical psychopharmacology.

[12]  Challis Gb.  Level of activity and prevalence of smoking in psychiatric patients. , 1999 .

[13]  G. Chouinard,et al.  Olanzapine-induced neuroleptic malignant syndrome with mental retardation. , 1999, The American journal of psychiatry.

[14]  J. Zislin,et al.  Marked Elevation of Serum Creatine Kinase Associated with Olanzapine Therapy , 1999, The Annals of pharmacotherapy.

[15]  S. Lippmann,et al.  Olanzapine and NMS. , 1999, Psychiatric services.

[16]  J. E. Apple,et al.  Neuroleptic malignant syndrome associated with olanzapine therapy. , 1999, Psychosomatics.

[17]  C. Emborg.  [Neuroleptic malignant syndrome after treatment with olanzapine]. , 1999, Ugeskrift for laeger.

[18]  Candace S. Brown,et al.  Atypical Antipsychotics: Part II Adverse Effects, Drug Interactions, and Costs , 1999, The Annals of pharmacotherapy.

[19]  T. Landis,et al.  Olanzapine-induced neuroleptic malignant syndrome. , 1999, Archives of general psychiatry.

[20]  P. R. M. Bittencourt,et al.  Síndrome neuroléptica maligna: relato de caso com recorrência associada ao uso de olanzapina , 1998 .

[21]  R. Coeytaux,et al.  Case report: possible neuroleptic malignant syndrome associated with olanzapine. , 1998, Journal of clinical psychopharmacology.

[22]  G. Bruxner,et al.  Neuroleptic Malignant Syndrome Associated with Olanzapine , 1998, The Australian and New Zealand journal of psychiatry.

[23]  C. Billington,et al.  Neuroleptic Malignant Syndrome Associated with Olanzapine , 1998, The Annals of pharmacotherapy.

[24]  P. Buckley,et al.  Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. , 1998, The American journal of psychiatry.

[25]  G. Tollefson,et al.  Safety of olanzapine. , 1997, The Journal of clinical psychiatry.

[26]  R. Pfeiffer,et al.  Pathogenesis and treatment of neuroleptic malignant syndrome. , 1990, General pharmacology.

[27]  P. Rosebush,et al.  A prospective analysis of 24 episodes of neuroleptic malignant syndrome. , 1989, The American journal of psychiatry.

[28]  A. Lazarus,et al.  Neuroleptic malignant syndrome. , 2000, Archives of general psychiatry.

[29]  P. Keck,et al.  Frequency and presentation of neuroleptic malignant syndrome: a prospective study. , 1987, The American journal of psychiatry.

[30]  P. Sachdev.  Lithium potentiation of neuroleptic-related extrapyramidal side effects. , 1986, The American journal of psychiatry.

[31]  G. Addonizio.  Rapid Induction of Extrapyramidal Side Effects with Combined Use of Lithium and Neuroleptics , 1985, Journal of clinical psychopharmacology.

[32]  S. Gershon,et al.  Lithium-induced accentuation of extrapyramidal symptoms in individuals with Alzheimer's disease. , 1984, The Journal of clinical psychiatry.

[33]  F. Mastaglia,et al.  Neuroleptic malignant syndrome , 1984, The Medical journal of Australia.

[34]  S. Gershon,et al.  Cogwheel rigidity related to lithium maintenance. , 1975, American Journal of Psychiatry.

[35]  S. Gershon,et al.  Effect of Lithium on Brain Dopamine , 1973, Nature.